Quizartinib (BioDeep_00000182830)

   

human metabolite blood metabolite Chemicals and Drugs


代谢物信息卡片


3-(5-tert-butyl-1,2-oxazol-3-yl)-1-(4-{10-[2-(morpholin-4-yl)ethoxy]-7-thia-2,5-diazatricyclo[6.4.0.0²,⁶]dodeca-1(8),3,5,9,11-pentaen-4-yl}phenyl)urea

化学式: C29H32N6O4S (560.2205632)
中文名称: 奎扎替尼
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC(C)(C)C1=CC(=NO1)NC(=O)NC2=CC=C(C=C2)C3=CN4C5=C(C=C(C=C5)OCCN6CCOCC6)SC4=N3
InChI: InChI=1S/C29H32N6O4S/c1-29(2,3)25-17-26(33-39-25)32-27(36)30-20-6-4-19(5-7-20)22-18-35-23-9-8-21(16-24(23)40-28(35)31-22)38-15-12-34-10-13-37-14-11-34/h4-9,16-18H,10-15H2,1-3H3,(H2,30,32,33,36)

描述信息

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor

同义名列表

10 个代谢物同义名

3-(5-tert-butyl-1,2-oxazol-3-yl)-1-(4-{10-[2-(morpholin-4-yl)ethoxy]-7-thia-2,5-diazatricyclo[6.4.0.0²,⁶]dodeca-1(8),3,5,9,11-pentaen-4-yl}phenyl)urea; N-(5-(1,1-Dimethylethyl)isoxazol-3-yl)-n-(4-(7-(2-(morpholin-4-yl)ethoxy)imidazo(2,1-b)benzothiazol-2-yl)phenyl)urea; Quizartinib (AC220); AC220 compound; Quizartinibum; Quizartinib; AC 010220; AC010220; AC 220; AC220



数据库引用编号

9 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Kouhei Yamawaki, Isamu Shiina, Takatsugu Murata, Satoru Tateyama, Yutarou Maekawa, Mariko Niwa, Motoyuki Shimonaka, Koji Okamoto, Toshihiro Suzuki, Toshirou Nishida, Ryo Abe, Yuuki Obata. FLT3-ITD transduces autonomous growth signals during its biosynthetic trafficking in acute myelogenous leukemia cells. Scientific reports. 2021 11; 11(1):22678. doi: 10.1038/s41598-021-02221-2. [PMID: 34811450]
  • Pierre-Yves Dumas, Arnaud Villacreces, Amélie V Guitart, Ali El-Habhab, Layal Massara, Olivier Mansier, Audrey Bidet, Delphine Martineau, Solene Fernandez, Thibaut Leguay, Arnaud Pigneux, Isabelle Vigon, Jean-Max Pasquet, Vanessa Desplat. Dual Inhibition of FLT3 and AXL by Gilteritinib Overcomes Hematopoietic Niche-Driven Resistance Mechanisms in FLT3-ITD Acute Myeloid Leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 11; 27(21):6012-6025. doi: 10.1158/1078-0432.ccr-20-3114. [PMID: 34400415]
  • François Hermetet, Rony Mshaik, John Simonet, Patrick Callier, Laurent Delva, Ronan Quéré. High-fat diet intensifies MLL-AF9-induced acute myeloid leukemia through activation of the FLT3 signaling in mouse primitive hematopoietic cells. Scientific reports. 2020 09; 10(1):16187. doi: 10.1038/s41598-020-73020-4. [PMID: 32999332]
  • Jisheng Liu, Yuting Wang, Chen Chen, Zhengchao Tu, Sihua Zhu, Fengtao Zhou, Hongfei Si, Canhui Zheng, Zhang Zhang, Qian Cai. Identification and Development of 1,4-Diaryl-1,2,3-triazolo-Based Ureas as Novel FLT3 Inhibitors. ACS medicinal chemistry letters. 2020 Aug; 11(8):1567-1572. doi: 10.1021/acsmedchemlett.0c00216. [PMID: 32832025]
  • Fangli Chen, Xue Wu, Cristina Niculite, Marilena Gilca, Daniela Petrusca, Adriana Rogozea, Susan Rice, Bin Guo, Shawn Griffin, George A Calin, H Scott Boswell, Heiko Konig. Classic and targeted anti-leukaemic agents interfere with the cholesterol biogenesis metagene in acute myeloid leukaemia: Therapeutic implications. Journal of cellular and molecular medicine. 2020 07; 24(13):7378-7392. doi: 10.1111/jcmm.15339. [PMID: 32450611]
  • Bai-Liang He, Ning Yang, Cheuk Him Man, Nelson Ka-Lam Ng, Chae-Yin Cher, Ho-Ching Leung, Leo Lai-Hok Kan, Bowie Yik-Ling Cheng, Stephen Sze-Yuen Lam, Michelle Lu-Lu Wang, Chun-Xiao Zhang, Hin Kwok, Grace Cheng, Rakesh Sharma, Alvin Chun-Hang Ma, Chi Wai Eric So, Yok-Lam Kwong, Anskar Yu-Hung Leung. Follistatin is a novel therapeutic target and biomarker in FLT3/ITD acute myeloid leukemia. EMBO molecular medicine. 2020 04; 12(4):e10895. doi: 10.15252/emmm.201910895. [PMID: 32134197]
  • Jianke Li, Melissa Holmes, Martin Kankam, Denise Trone, Jeanne Mendell, Guy Gammon. Effect of Food on the Pharmacokinetics of Quizartinib. Clinical pharmacology in drug development. 2020 02; 9(2):277-286. doi: 10.1002/cpdd.770. [PMID: 31916418]
  • Ruifeng Wang, Titi Chen, Chengshi Wang, Zhiqiang Zhang, Xin Maggie Wang, Qing Li, Vincent W S Lee, Yuan Min Wang, Guoping Zheng, Stephen I Alexander, Yiping Wang, David C H Harris, Qi Cao. Flt3 inhibition alleviates chronic kidney disease by suppressing CD103+ dendritic cell-mediated T cell activation. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2019 11; 34(11):1853-1863. doi: 10.1093/ndt/gfy385. [PMID: 30590794]
  • Jianke Li, Denise Trone, Jeanne Mendell, Patrick O'Donnell, Natalie Cook. A drug-drug interaction study to assess the potential effect of acid-reducing agent, lansoprazole, on quizartinib pharmacokinetics. Cancer chemotherapy and pharmacology. 2019 10; 84(4):799-807. doi: 10.1007/s00280-019-03915-1. [PMID: 31385001]
  • Jianke Li, Martin Kankam, Denise Trone, Guy Gammon. Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite. British journal of clinical pharmacology. 2019 09; 85(9):2108-2117. doi: 10.1111/bcp.14022. [PMID: 31173645]
  • Woo-Sung Kwon, Ye-Ji Kim, Do-Yeal Ryu, Ki-Jin Kwon, Won-Hee Song, Md Saidur Rahman, Myung-Geol Pang. Fms-like tyrosine kinase 3 is a key factor of male fertility. Theriogenology. 2019 Mar; 126(?):145-152. doi: 10.1016/j.theriogenology.2018.12.019. [PMID: 30553232]
  • Jing Wang, Changpei Gan, Irene A Retmana, Rolf W Sparidans, Wenlong Li, Maria C Lebre, Jos H Beijnen, Alfred H Schinkel. P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice. International journal of pharmaceutics. 2019 Feb; 556(?):172-180. doi: 10.1016/j.ijpharm.2018.12.014. [PMID: 30553002]
  • Essam Ezzeldin, Muzaffar Iqbal, Gamal Mostafa, Khalid A Al-Rashood, Toqa El-Nahhas. Method development for quantification of quizartinib in rat plasma by liquid chromatography/tandem mass spectrometry for pharmacokinetic application. Biomedical chromatography : BMC. 2018 Mar; 32(3):. doi: 10.1002/bmc.4131. [PMID: 29131376]
  • Madhu Sanga, Joyce James, Joseph Marini, Guy Gammon, Christine Hale, Jianke Li. An open-label, single-dose, phase 1 study of the absorption, metabolism and excretion of quizartinib, a highly selective and potent FLT3 tyrosine kinase inhibitor, in healthy male subjects, for the treatment of acute myeloid leukemia. Xenobiotica; the fate of foreign compounds in biological systems. 2017 Oct; 47(10):856-869. doi: 10.1080/00498254.2016.1217100. [PMID: 27460866]
  • Irene A Retmana, Jing Wang, Alfred H Schinkel, Jan H M Schellens, Jos H Beijnen, Rolf W Sparidans. Liquid chromatography-tandem mass spectrometric assay for the quantitative determination of the tyrosine kinase inhibitor quizartinib in mouse plasma using salting-out liquid-liquid extraction. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2017 Sep; 1061-1062(?):300-305. doi: 10.1016/j.jchromb.2017.07.034. [PMID: 28772226]
  • Todd M Cooper, Jeannette Cassar, Elena Eckroth, Jemily Malvar, Richard Sposto, Paul Gaynon, Bill H Chang, Lia Gore, Keith August, Jessica A Pollard, Steven G DuBois, Lewis B Silverman, Javier Oesterheld, Guy Gammon, Daniel Magoon, Colleen Annesley, Patrick A Brown. A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Aug; 22(16):4014-22. doi: 10.1158/1078-0432.ccr-15-1998. [PMID: 26920889]
  • Yaping Zhang, Cheng-Pang Hsu, Jian-Feng Lu, Mita Kuchimanchi, Yu-Nien Sun, Ji Ma, Guifen Xu, Yilong Zhang, Yang Xu, Margaret Weidner, Justin Huard, David Z D'Argenio. FLT3 and CDK4/6 inhibitors: signaling mechanisms and tumor burden in subcutaneous and orthotopic mouse models of acute myeloid leukemia. Journal of pharmacokinetics and pharmacodynamics. 2014 Dec; 41(6):675-91. doi: 10.1007/s10928-014-9393-x. [PMID: 25326874]
  • Jorge E Cortes, Hagop Kantarjian, James M Foran, Darejan Ghirdaladze, Mamia Zodelava, Gautam Borthakur, Guy Gammon, Denise Trone, Robert C Armstrong, Joyce James, Mark Levis. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Oct; 31(29):3681-7. doi: 10.1200/jco.2013.48.8783. [PMID: 24002496]